The extracellular matrix protein EMILIN1 (elastin microfibril interface located protein 1) is implicated in maintaining blood pressure homeostasis via the N-terminal elastin microfibril interface domain and in trophoblast invasion of the uterine wall via the globular C1q (gC1q) domain. Here, we describe the first NMR-based homology model structure of the human 52-kDa homotrimer of the EMILIN1 gC1q domain. In contrast to all of the gC1q (crystal) structures solved to date, the 10-stranded -sandwich fold of the gC1q domain is reduced to nine  strands with a consequent increase in the size of the central cavity lumen. An unstructured loop, resulting from an insertion unique to EMILIN1 and EMILIN2 family members and located at the trimer apex upstream of the missing strand, specifically engages the ␣41 integrin. Using both Jurkat T and EA.hy926 endothelial cells as well as site-directed mutagenesis, we demonstrate that the ability of ␣41 integrins to recognize the trimeric EMILIN1 gC1q domain mainly depends on a single glutamic acid residue (Glu 933 ). Static and flow adhesion of T cells and haptotactic migration of endothelial cells on gC1q is fully dependent on this residue. Thus, EMILIN1 gC1q-␣41 represents a unique ligand/receptor system, with a requirement for a 3-fold arrangement of the interaction site.EMILIN1 (elastin microfibril interface located protein 1) is a secreted extracellular matrix multidomain glycoprotein (1, 2). It is characterized by a unique arrangement of structural domains, including the elastin microfibril interface domain at the N terminus, an ␣-helical domain predicted to form a coiledcoil structure in the central part of the molecule, a short collagenous sequence, and a region homologous to the globular domain of C1q (gC1q domain) 4 at the C-terminal end (3, 4). Although the role of the coiled-coil region has not yet been elucidated, it has conclusively been demonstrated that EMILIN1 interacts with pro-tumor growth factor- (5) through the elastin microfibril interface domain (6). EMILIN1 deficiency causes systemic arterial hypertension, and the expression of EMILIN1 at physiological levels by binding to pro-tumor growth factor- prevents its maturation by protein convertases (5). Thus, EMILIN1 favorably located at the subendothelium of blood vessels is a new specific antagonist of tumor growth factor-, and the function of this constituent of elastic tissues is linked to the pathogenesis of hypertension. The C-terminal gC1q domain is involved in the oligomerization of EMILIN1 (7), in cell adhesion and migration via interaction with the ␣41 integrin (8), and in trophoblast invasion (9).The gC1q signature is found in a variety of proteins, and the essential features of the specific structure-function relationship were recognized with the elucidation of the crystal structure of the homotrimeric gC1q domain of mouse ACRP30 (adipocyte complement-related protein of 30 kDa) (10). It suggested a structural and evolutionary link between the tumor necrosis factor and the gC1q domains and le...
The extracellular matrix glycoprotein EMILIN1 exerts a wide range of functions mainly associated with its gC1q domain. Besides providing functional significance for adhesion and migration, the direct interaction between α4β1 integrin and EMILIN1-gC1q regulates cell proliferation, transducing net anti-proliferative effects. We have previously demonstrated that EMILIN1 degradation by neutrophil elastase (NE) is a specific mechanism leading to the loss of functions disabling its regulatory properties. In this study we further analysed the proteolytic activity of NE, MMP-3, MMP-9, and MT1-MMP on EMILIN1 and found that MMP-3 and MT1-MMP partially cleaved EMILIN1 but without affecting the functional properties associated with the gC1q domain, whereas NE was able to fully impair the interaction of gC1q with the α4β1 integrin by cleaving this domain outside of the E933 integrin binding site. By a site direct mutagenesis approach we mapped the bond between S913 and R914 residues and selected the NE-resistant R914W mutant still able to interact with the α4β1 integrin after NE treatment. Functional studies showed that NE impaired the EMILIN1-α4β1 integrin interaction by cleaving the gC1q domain in a region crucial for its proper structural conformation, paving the way to better understand NE effects on EMILIN1-cell interaction in pathological context.
Gastric cancer is a deadly tumor and a relatively common disease worldwide. Surgical resection and chemotherapy are the main clinical options to treat this type of disease, however the median overall survival rate is limited to one year. Thus, the development of new therapies is a highly necessary clinical need. Angiogenesis is a promising target for this tumor type, however clinical trials with the use of anti-angiogenic drugs have so far not met expectations. Therefore, it is important to better characterize the expression of molecules whose expression levels may impact on the efficacy of the treatments. In this study the characteristics of the gastric tumor associated blood vessels were first assessed by endomicroscopy. Next, we analyzed the expression of Multimerin-2, EMILIN-2 and EMILIN-1, three molecules of the EMI Domain ENdowed (EDEN) protein family. These molecules play important functions in the tumor microenvironment, affecting cancer progression both directly and indirectly impinging on angiogenesis and lymphangiogenesis. All the molecules were highly expressed in the normal mucosa whereas in a number of patients their expression was altered. We consider that better characterizing the gastric tumor microenvironment and the quality of the vasculature may achieve effective patient tailored therapies.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.